355
Participants
Start Date
July 24, 2018
Primary Completion Date
January 31, 2024
Study Completion Date
January 31, 2024
Pyrotinib
pyrotinib: 400mg orally daily;
Placebo Oral Tablet
placebo: 400mg orally daily;
Trastuzumab
trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 4 cycles;
Docetaxel
docetaxel:after the biological window, 100mg/m2 for a total of 4 cycles
Peking University People's Hospital, Beijing
The Fifth Medical Center of Chinese PLA General Hospital, Beijing
Fudan University Shanghai Cancer Center, Shanghai
JiangSu Province Hospital, Nanjing
Huai'an First People's Hospital, Huaian
Shandong Cancer Hospital, Jinan
The Affiliated Hospital Of Qingdao University, Qingdao
The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou
Fujian Medical University Union Hospital, Fuzhou
The affiliated cancer hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou
Sun Yet-Sen University Cancer Center, Guangzhou
Guangdong Provincial People's Hospital, Guangzhou
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou
The Second Affiliated Hospital Of Xi'an Jiaotong University, Xian
The Fourth Hospital of Hebei Medical University, Shijiazhuang
Jiangsu HengRui Medicine Co., Ltd.
INDUSTRY